ATE449789T1 - Pacap-peptidanaloga - Google Patents

Pacap-peptidanaloga

Info

Publication number
ATE449789T1
ATE449789T1 AT99920844T AT99920844T ATE449789T1 AT E449789 T1 ATE449789 T1 AT E449789T1 AT 99920844 T AT99920844 T AT 99920844T AT 99920844 T AT99920844 T AT 99920844T AT E449789 T1 ATE449789 T1 AT E449789T1
Authority
AT
Austria
Prior art keywords
peptide analogue
pacap peptide
pacap
analogue
peptide
Prior art date
Application number
AT99920844T
Other languages
English (en)
Inventor
Zheng Dong
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE449789T1 publication Critical patent/ATE449789T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
AT99920844T 1998-07-20 1999-04-30 Pacap-peptidanaloga ATE449789T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11954098A 1998-07-20 1998-07-20
PCT/EP1999/003020 WO2000005260A1 (en) 1998-07-20 1999-04-30 Peptide analogues of pacap

Publications (1)

Publication Number Publication Date
ATE449789T1 true ATE449789T1 (de) 2009-12-15

Family

ID=22384966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920844T ATE449789T1 (de) 1998-07-20 1999-04-30 Pacap-peptidanaloga

Country Status (15)

Country Link
EP (2) EP1098906B1 (de)
JP (2) JP2002521390A (de)
AR (1) AR019131A1 (de)
AT (1) ATE449789T1 (de)
AU (1) AU3826899A (de)
CA (1) CA2335341A1 (de)
CZ (1) CZ2001253A3 (de)
DE (1) DE69941708D1 (de)
DK (1) DK1098906T3 (de)
ES (1) ES2335827T3 (de)
HU (1) HUP0104934A3 (de)
NO (1) NO20010284L (de)
PL (1) PL345583A1 (de)
TW (1) TWI221845B (de)
WO (1) WO2000005260A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
SK5552002A3 (en) * 1999-09-28 2003-05-02 Bayer Ag Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
JP2004500906A (ja) 1999-11-12 2004-01-15 ルーベン，　レオ 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド
EP1257575B1 (de) * 2000-02-18 2007-02-28 Dabur Research Foundation Radiomarkierte vip-analoge zur diagnose und therapie
EP1257576B1 (de) 2000-02-18 2004-09-15 Dabur Research Foundation Vip-analoge
CA2428552A1 (en) * 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
JP2002293799A (ja) * 2001-03-29 2002-10-09 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
AR036400A1 (es) 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
WO2003024472A2 (en) * 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
AU2003228050A1 (en) * 2002-05-03 2003-11-17 Neuronova Ab Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders
DE60326723D1 (de) * 2002-06-10 2009-04-30 Mondobiotech Licensing Out Ag Verwendung von zusammensetzungen mit der biologischen aktivität der vasoaktiven intestinalen peptide zur behandlung von sarcoidose
CA2492442A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
EP1583550A2 (de) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Behandlung von thrombozytopenie mit hilfe von pacap-inhibitoren
AU2005211847B2 (en) 2004-02-13 2011-02-24 Stem Cell Therapeutics Corp. Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
JP2006306770A (ja) * 2005-04-27 2006-11-09 Nidek Co Ltd 眼疾患治療剤
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
WO2007050651A1 (en) 2005-10-26 2007-05-03 Eli Lilly And Company Selective vpac2 receptor peptide agonists
AU2010313122A1 (en) * 2009-11-02 2012-05-24 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
SG11201506407VA (en) * 2013-02-15 2015-09-29 Univ Jefferson Kit for tumor imaging
EP3683237A1 (de) 2013-03-15 2020-07-22 Amgen Inc. Humane pac1-antikörper
EP3019184A4 (de) * 2013-06-07 2017-04-05 The Administrators of the Tulane Educational Fund Analoga des pituitären adenylatcyclase-aktivierenden polypeptids (pacap) und verfahren zu deren verwendung
WO2015023890A1 (en) * 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
CA2930330A1 (en) * 2013-12-27 2015-07-02 Dignity Health Diagnosing and treating alzheimer's disease
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
CA3049212A1 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS277405B6 (en) * 1986-06-12 1993-03-17 Vyzk Ustav Farm Biochem Sp Peptides with 1-amino-1-cycloalkane carboxylic acid
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
JP3354173B2 (ja) * 1991-08-22 2002-12-09 武田薬品工業株式会社 ポリペプチドおよびその用途
WO1996009318A1 (en) * 1994-09-22 1996-03-28 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
EP0820296A4 (de) * 1995-04-14 1999-06-30 Univ Tulane Analoge von wachstumshormon-freisetzungsfaktor
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
AU682638B2 (en) * 1995-06-09 1997-10-09 ILS, Inc. Peptide, bronchodilator and blood flow ameliorant
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
WO1997007452A1 (en) * 1995-08-15 1997-02-27 International Software Machines Programmable compiler

Also Published As

Publication number Publication date
NO20010284L (no) 2001-03-19
WO2000005260A1 (en) 2000-02-03
ES2335827T3 (es) 2010-04-05
AU3826899A (en) 2000-02-14
PL345583A1 (en) 2001-12-17
CZ2001253A3 (cs) 2001-11-14
HUP0104934A3 (en) 2002-05-28
AR019131A1 (es) 2001-12-26
DK1098906T3 (da) 2010-03-29
EP2161282A1 (de) 2010-03-10
EP1098906A1 (de) 2001-05-16
CA2335341A1 (en) 2000-02-03
JP2002521390A (ja) 2002-07-16
NO20010284D0 (no) 2001-01-17
HUP0104934A2 (hu) 2002-04-29
JP2010189398A (ja) 2010-09-02
TWI221845B (en) 2004-10-11
EP1098906B1 (de) 2009-11-25
DE69941708D1 (de) 2010-01-07

Similar Documents

Publication Publication Date Title
ATE449789T1 (de) Pacap-peptidanaloga
NO982097D0 (no) Peptider
NO982098D0 (no) Peptider
EE200100080A (et) C-hepatiidi inhibiitorpeptiidid
ATE228357T1 (de) Nukleotid-analoge zusammensetzung
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
ATE288410T1 (de) Vitamin d-analoga
DE59902471D1 (de) Kommissionieranlage
ATE321784T1 (de) Pthrp analogen
DE59910376D1 (de) Schleuderstreuer
NO985680L (no) Peptidderivater
DE69902762T2 (de) Riser-spannanordnung
FR2787514B1 (fr) Propulseur
NO983849L (no) Peptidderivater
DE19982534D2 (de) Spriegelausführung
ID30477A (id) Analog nukleosida antivirus
DK0862850T3 (da) Mejetærsker
ATE295417T1 (de) Angiostatin-bindendes protein
FR2782671B3 (fr) Livre
NO20002555L (no) Skjøt
DE1039711T1 (de) Digitaler demodulatior
NO20012283D0 (no) Koblede peptider
KR980000237U (ko) 넥타이
ID26084A (id) Turunan-turunan amino antrasiklinon
KR970053212U (ko) 넥타이

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties